Safe oral intakes for pharmaceutical excipients
Client
A manufacturer of pharmaceuticals.
Background
Bibra was asked to consider the available toxicity data on two pharmaceutical excipients, and to propose tolerable oral intakes (i.e. health criteria values (HCVs)) for patients.
Project goals
To perform comprehensive literature searches on both excipients, identifying, where available, key Expert Group pronouncements on toxicity and derivations of oral HCVs. If no suitable HCVs were identified, bibra was asked to derive its own HCVs for each excipient.
Approach
Bibra reviewed and summarised the available toxicity data on each (relatively well-studied) excipient, including a consideration of Expert Group opinions and tolerable intakes. Bibra provided its conclusions on the suitability and magnitude of oral HCVs for the two chemicals.
Bibra project team
Beth O’Connell
Pete Watts
Pharmaceuticals
More recent work Info about us Meet our team